Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist, for atopic dermatitis
14th June 2016
Dermatology
Related To This Subject
![EMJ Dermatology 10 [Infographic Supplement 2] 2022 Feature Image](https://emj.emg-health.com/wp-content/uploads/sites/2/2022/02/EMJ-Dermatology-10-Infographic-Supplement-2-2022-Feature-Image-940x522.jpg)
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now